



Clinical trial results:

A phase Ib, open-label study of oral BGJ398 in combination with oral BYL719 in adult patients with select advanced solid tumors

Summary

EudraCT number	2013-001018-14
Trial protocol	DE BE NL
Global end of trial date	23 August 2016

Results information

Result version number	v1 (current)
This version publication date	02 September 2017
First version publication date	02 September 2017

Trial information

Trial identification

Sponsor protocol code	CBGJ398X2102
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01928459
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharmaceuticals AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Novartis Pharmaceuticals AG, Novartis Pharmaceuticals AG, +41 613241111,
Scientific contact	Novartis Pharmaceuticals AG, Novartis Pharmaceuticals AG, +41 613241111,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 August 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	23 August 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulator requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 October 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 4
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Singapore: 2
Country: Number of subjects enrolled	Switzerland: 1
Country: Number of subjects enrolled	United States: 23
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Spain: 14
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Germany: 6
Country: Number of subjects enrolled	Italy: 2
Worldwide total number of subjects	62
EEA total number of subjects	30

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	43
From 65 to 84 years	19
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

At the time of the data cut-off date (23-Aug-2016), all patients had discontinued treatment. All 62 patients received at least one dose of BGJ398 or BYL719 and had at least one valid post-baseline safety assessment and were included in the FAS and Safety.

Pre-assignment

Screening details:

28 patients in the dose escalation part met the minimum exposure criterion and safety evaluation requirements and were included in the dose determining set (DDS). 58 were included in the pharmacokinetic analysis set (PAS), with only 4 patients, across three dose levels, excluded for not having at least one blood sample providing evaluable PK.

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	BGJ398 20mg + BYL719 300mg

Arm description:

All patients, in both the dose escalation and dose expansion parts, were assigned to combination treatment with BGJ398 and BYL719. The starting dose of BGJ398 was 20 mg once daily on a 3 weeks on/1 week off schedule, which is 16% of the MTD identified in the first-in-human BGJ398 study [Study BGJ398X2101], as well as the lowest dose of BGJ398 that generated plasma concentrations that were consistently above the limit of quantitation. The starting dose of BYL719 for this study was 300 mg once daily, which is 75% of the MTD for BYL719 identified in the Phase 1 clinical study [Study BYL719X2101] but still associated with clinical activity. The starting dose of BYL719 was reduced to 300 mg once daily to address the potential of increased exposure to BYL719 when combined with BGJ398.

Arm type	Experimental
Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard, Gel
Routes of administration	Oral use

Dosage and administration details:

BGJ398 hard gelatin capsules for oral use were supplied at dosage strengths of 5 mg, 25 mg, 100 mg, and 120 mg.

Patients received BGJ398 once daily for the first 21 days of the 28-day cycle followed by a 7-day (1-week) break.

Investigational medicinal product name	BYL719
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

BYL719 film-coated tablets for oral use were supplied at dosage strengths of 10 mg, 50 mg, and 200 mg.

Patients received BYL719 once daily continuously on a 28-day cycle.

Arm title	BGJ398 20mg + BYL719 400mg
Arm description: -	
Arm type	Experimental

Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard, Gel
Routes of administration	Oral use

Dosage and administration details:

BGJ398 hard gelatin capsules for oral use were supplied at dosage strengths of 5 mg, 25 mg, 100 mg, and 120 mg.

Patients received BGJ398 once daily for the first 21 days of the 28-day cycle followed by a 7-day (1-week) break.

Investigational medicinal product name	BYL719
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

BYL719 film-coated tablets for oral use were supplied at dosage strengths of 10 mg, 50 mg, and 200 mg.

Patients received BYL719 once daily continuously on a 28-day cycle.

Arm title	BGJ398 40mg + BYL719 300mg
------------------	----------------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard, Gel
Routes of administration	Oral use

Dosage and administration details:

BGJ398 hard gelatin capsules for oral use were supplied at dosage strengths of 5 mg, 25 mg, 100 mg, and 120 mg.

Patients received BGJ398 once daily for the first 21 days of the 28-day cycle followed by a 7-day (1-week) break.

Investigational medicinal product name	BYL719
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

BYL719 film-coated tablets for oral use were supplied at dosage strengths of 10 mg, 50 mg, and 200 mg.

Patients received BYL719 once daily continuously on a 28-day cycle.

Arm title	BGJ398 75mg + BYL719 300mg
------------------	----------------------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard, Gel
Routes of administration	Oral use

Dosage and administration details:

BGJ398 hard gelatin capsules for oral use were supplied at dosage strengths of 5 mg, 25 mg, 100 mg, and 120 mg.

Patients received BGJ398 once daily for the first 21 days of the 28-day cycle followed by a 7-day (1-week) break.

Investigational medicinal product name	BYL719
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

BYL719 film-coated tablets for oral use were supplied at dosage strengths of 10 mg, 50 mg, and 200 mg.

Patients received BYL719 once daily continuously on a 28-day cycle.

Arm title	BGJ398 90mg + BYL719 300mg
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard, Gel
Routes of administration	Oral use

Dosage and administration details:

BGJ398 hard gelatin capsules for oral use were supplied at dosage strengths of 5 mg, 25 mg, 100 mg, and 120 mg.

Patients received BGJ398 once daily for the first 21 days of the 28-day cycle followed by a 7-day (1-week) break.

Investigational medicinal product name	BYL719
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

BYL719 film-coated tablets for oral use were supplied at dosage strengths of 10 mg, 50 mg, and 200 mg.

Patients received BYL719 once daily continuously on a 28-day cycle.

Arm title	BGJ398 100mg + BYL719 300mg
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard, Gel
Routes of administration	Oral use

Dosage and administration details:

BGJ398 hard gelatin capsules for oral use were supplied at dosage strengths of 5 mg, 25 mg, 100 mg, and 120 mg.

Patients received BGJ398 once daily for the first 21 days of the 28-day cycle followed by a 7-day (1-week) break.

Investigational medicinal product name	BYL719
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

BYL719 film-coated tablets for oral use were supplied at dosage strengths of 10 mg, 50 mg, and 200 mg.

Patients received BYL719 once daily continuously on a 28-day cycle.

Arm title	BGJ398 125mg + BYL719 300mg
------------------	-----------------------------

Arm description: -	
Arm type	Experimental
Investigational medicinal product name	BGJ398
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard, Gel
Routes of administration	Oral use

Dosage and administration details:

BGJ398 hard gelatin capsules for oral use were supplied at dosage strengths of 5 mg, 25 mg, 100 mg, and 120 mg.

Patients received BGJ398 once daily for the first 21 days of the 28-day cycle followed by a 7-day (1-week) break.

Investigational medicinal product name	BYL719
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

BYL719 film-coated tablets for oral use were supplied at dosage strengths of 10 mg, 50 mg, and 200 mg.

Patients received BYL719 once daily continuously on a 28-day cycle.

Number of subjects in period 1	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg
Started	4	4	6
Completed	0	0	0
Not completed	4	4	6
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	1	-	-
Progressive disease	3	4	6
Protocol deviation	-	-	-

Number of subjects in period 1	BGJ398 75mg + BYL719 300mg	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg
Started	6	5	6
Completed	0	0	0
Not completed	6	5	6
Consent withdrawn by subject	1	1	-
Adverse event, non-fatal	1	1	1
Progressive disease	4	3	5
Protocol deviation	-	-	-

Number of subjects in period 1	BGJ398 125mg + BYL719 300mg
Started	31
Completed	0
Not completed	31
Consent withdrawn by subject	3

Adverse event, non-fatal	4
Progressive disease	23
Protocol deviation	1

Baseline characteristics

Reporting groups

Reporting group title	BGJ398 20mg + BYL719 300mg
Reporting group description:	
All patients, in both the dose escalation and dose expansion parts, were assigned to combination treatment with BGJ398 and BYL719. The starting dose of BGJ398 was 20 mg once daily on a 3 weeks on/1 week off schedule, which is 16% of the MTD identified in the first-in-human BGJ398 study [Study BGJ398X2101], as well as the lowest dose of BGJ398 that generated plasma concentrations that were consistently above the limit of quantitation. The starting dose of BYL719 for this study was 300 mg once daily, which is 75% of the MTD for BYL719 identified in the Phase 1 clinical study [Study BYL719X2101] but still associated with clinical activity. The starting dose of BYL719 was reduced to 300 mg once daily to address the potential of increased exposure to BYL719 when combined with BGJ398.	
Reporting group title	BGJ398 20mg + BYL719 400mg
Reporting group description: -	
Reporting group title	BGJ398 40mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 75mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 90mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 100mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 125mg + BYL719 300mg
Reporting group description: -	

Reporting group values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg
Number of subjects	4	4	6
Age categorical			
Units: Subjects			
Adults (18-64 years)	3	4	3
From 65-84 years	1	0	3
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	56	49.8	62.8
standard deviation	± 10.42	± 11.59	± 8.66
Gender categorical			
Units: Subjects			
Female	4	3	3
Male	0	1	3

Reporting group values	BGJ398 75mg + BYL719 300mg	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg
Number of subjects	6	5	6
Age categorical			
Units: Subjects			
Adults (18-64 years)	4	1	3
From 65-84 years	2	4	3
85 years and over	0	0	0

Age continuous Units: years arithmetic mean standard deviation	63 ± 7.13	65.4 ± 3.29	63.2 ± 11.58
Gender categorical Units: Subjects			
Female	5	2	5
Male	1	3	1

Reporting group values	BGJ398 125mg + BYL719 300mg	Total	
Number of subjects	31	62	
Age categorical Units: Subjects			
Adults (18-64 years)	25	43	
From 65-84 years	6	19	
85 years and over	0	0	
Age continuous Units: years arithmetic mean standard deviation	56.1 ± 10.81	-	
Gender categorical Units: Subjects			
Female	17	39	
Male	14	23	

End points

End points reporting groups

Reporting group title	BGJ398 20mg + BYL719 300mg
Reporting group description: All patients, in both the dose escalation and dose expansion parts, were assigned to combination treatment with BGJ398 and BYL719. The starting dose of BGJ398 was 20 mg once daily on a 3 weeks on/1 week off schedule, which is 16% of the MTD identified in the first-in-human BGJ398 study [Study BGJ398X2101], as well as the lowest dose of BGJ398 that generated plasma concentrations that were consistently above the limit of quantitation. The starting dose of BYL719 for this study was 300 mg once daily, which is 75% of the MTD for BYL719 identified in the Phase 1 clinical study [Study BYL719X2101] but still associated with clinical activity. The starting dose of BYL719 was reduced to 300 mg once daily to address the potential of increased exposure to BYL719 when combined with BGJ398.	
Reporting group title	BGJ398 20mg + BYL719 400mg
Reporting group description: -	
Reporting group title	BGJ398 40mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 75mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 90mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 100mg + BYL719 300mg
Reporting group description: -	
Reporting group title	BGJ398 125mg + BYL719 300mg
Reporting group description: -	
Subject analysis set title	Escalation BGJ398 125mg + BYL719 300mg
Subject analysis set type	Full analysis
Subject analysis set description: All patients treated at Recommended Dose for Expansion (RDE).	
Subject analysis set title	Expansion Treatment Arm 1
Subject analysis set type	Full analysis
Subject analysis set description: Breast cancer patients with PIK3CA mutation and Fibroblast Growth Factor Receptor (FGFR) alteration (amplification, mutation or translocation).	
Subject analysis set title	Expansion Treatment Arm 2
Subject analysis set type	Full analysis
Subject analysis set description: Patients, regardless of primary site of cancer, with PIK3CA mutation and no FGFR alteration. Two patients with breast cancer and no FGFR alteration were included in this arm.	
Subject analysis set title	Expansion Treatment Arm 3
Subject analysis set type	Full analysis
Subject analysis set description: Non-breast cancer patients with PIK3CA mutation and FGFR alteration.	

Primary: Posterior distribution of DLT rates at the time of the last dose-escalation meeting

End point title	Posterior distribution of DLT rates at the time of the last dose-escalation meeting ^[1]
End point description: The primary variable in the study was the incidence rate of Dose-Limiting Toxicity (DLTs) in the 1st cycle of study treatment for patients with histologically/cytologically confirmed advanced or metastatic solid tumors carrying a PIK3CA mutation ± any FGFR genetic alterations, who have failed standard therapy and for whom no effective standard therapy exists in the Dose-Determining Set (DDS). Declaration of the Maximum-Tolerated Dose/Recommended dose for expansion (MTD/RDE) of the BGJ398 and BYL719 combination was guided by the probability of true DLT rate in Cycle 1 for patients in	

the DDS. This probability was estimated by the 5-parameter Bayesian logistic regression model (BLRM) guided by the escalation with overdose control (EWOC) principle. The DDS included all patients from the Safety set, and who were enrolled in the dose escalation part of the study, who either completed a minimum exposure requirement and had sufficient safety evaluations or experienced a DLT during Cycle 1

End point type	Primary
----------------	---------

End point timeframe:

first cycle (28-days; approximately 1 year)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Bayesian analyses were used for this trial. The Bayesian modeling of the dose-toxicity relationship used for dose-escalation decision making and inference for the MTD was performed using internal Novartis R library functions (OncoBayes) created by Novartis's Methodology group and was run using R version 3-2.3 in MODESIM/GPSII environment. We were not able to show these analyses here because they were in between doses and not groups as this is a single-arm treatment trial.

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	6	6
Units: Posterior probabilities (%)				
number (not applicable)				
[0 - 0.16)	0.905	0.545	0.888	0.766
[0.16 - 0.35)	0.095	0.442	0.111	0.233
[0.35 - 1]	0.001	0.013	0	0.001

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	6	31	
Units: Posterior probabilities (%)				
number (not applicable)				
[0 - 0.16)	0.683	0.632	0.542	
[0.16 - 0.35)	0.313	0.359	0.404	
[0.35 - 1]	0.004	0.009	0.054	

Statistical analyses

No statistical analyses for this end point

Primary: Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 in dose escalation Phase

End point title	Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 in dose escalation Phase ^[2]
-----------------	---

End point description:

Analyses for DLTs done in the DDS across all dose levels by primary system order class (SOC) and preferred terms.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 (28-day cycle; approximately 1 year)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Bayesian analyses were used for this trial. The Bayesian modeling of the dose-toxicity relationship used for dose-escalation decision making and inference for the MTD was performed using internal Novartis R library functions (OncoBayes) created by Novartis's Methodology group and was run using R version 3-2.3 in MODESIM/GPSII environment. We were not able to show these analyses here because they were in between doses and not groups as this is a single-arm treatment trial.

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	5	5
Units: Number of participants				
Any primary system organ class	0	0	1	1
GASTROINTESTINAL DISORDERS (SOC)	0	0	0	1
Stomatitis (Preferred term)	0	0	0	1
METABOLISM AND NUTRITION DISORDERS (SOC)	0	0	1	0
Hyperglycaemia (Preferred term)	0	0	1	0

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3	4	6	
Units: Number of participants				
Any primary system organ class	0	1	0	
GASTROINTESTINAL DISORDERS (SOC)	0	1	0	
Stomatitis (Preferred term)	0	1	0	
METABOLISM AND NUTRITION DISORDERS (SOC)	0	0	0	
Hyperglycaemia (Preferred term)	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Best Overall Response by Treatment as per RECIST 1.1

End point title	Best Overall Response by Treatment as per RECIST 1.1
End point description:	
Clinical anti-tumor activity of BGJ398 and BYL719 combination was evaluated locally by the Investigator according to the Novartis guideline (Version 3.0) based on RECIST version 1.1 based on overall response rate (ORR: CR (Complete Response) + PR (Partial Response)) corresponding to disease control rate (DCR) i.e. best overall response of Stable Disease (SD). Analysis was done in the Full Analysis Set (FAS). FAS included all patients who received at least one dose of BGJ398 or BYL719. Patients were classified according to the planned treatment combination. The FAS was used for all listings of raw data. Unless otherwise specified, the FAS was the default analysis set used for all analyses.	
End point type	Secondary

End point timeframe:

Throughout the duration of the trial (approximately 3 years)

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4	6	6
Units: Number of Subjects				
Overall response rate (ORR) (CR or PR)	0	0	0	1
Disease control rate (DCR) (CR or PR or SD)	2	3	3	3

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	6	31	
Units: Number of Subjects				
Overall response rate (ORR) (CR or PR)	1	0	4	
Disease control rate (DCR) (CR or PR or SD)	4	0	19	

Statistical analyses

No statistical analyses for this end point

Secondary: Best Overall Response by Treatment as per RECIST 1.1 - patients treated at MTD/RDE

End point title	Best Overall Response by Treatment as per RECIST 1.1 - patients treated at MTD/RDE
-----------------	--

End point description:

Tumor response was evaluated locally by the Investigator according to the Novartis guideline (Version 3.0) based on RECIST version 1.1.

Analysis was done in the FAS.

MTD/RDE = Maximum tolerated dose/Recommended dose for expansion

The BOR was summarized by treatment group for all patients and by treatment arms for patients treated at the MTD/RDE (1 cohort of patients in escalation part and 3 expansion arms).

End point type	Secondary
----------------	-----------

End point timeframe:

Throughout the duration of the trial ((approximately 3 years)

End point values	Escalation BGJ398 125mg + BYL719 300mg	Expansion Treatment Arm 1	Expansion Treatment Arm 2	Expansion Treatment Arm 3
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	5	12	6
Units: Number of subjects				
Overall response rate (ORR) (CR or PR)	0	0	2	2
Disease control rate (DCR) (CR or PR or SD)	4	2	8	4

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (PFS) per RECIST 1.1 for patients treated at MTD/RDE

End point title	Progression-Free Survival (PFS) per RECIST 1.1 for patients treated at MTD/RDE
End point description:	
Analysis was done the FAS. PFS is defined as the time from the start date of study treatment to the date of the first documented disease progression or death due to any cause. PFS was provided for patients at MTD/RDE for each treatment arm.	
End point type	Secondary
End point timeframe:	
Until disease progression or intolerable toxicity (approximately 3 years)	

End point values	Escalation BGJ398 125mg + BYL719 300mg	Expansion Treatment Arm 1	Expansion Treatment Arm 2	Expansion Treatment Arm 3
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	5	12	6
Units: Number of PFS Events				
Progression	4	2	10	4
Death	0	1	0	0
No. of censored	3	2	2	2

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration-Time Curve from Time Zero to 24 hour Post Dose for BGJ398 by Treatment

End point title	Area Under the Concentration-Time Curve from Time Zero to 24 hour Post Dose for BGJ398 by Treatment
-----------------	---

End point description:

Pharmacokinetic parameter for BGJ398.

$AUC(0-24hr) = [mass \times time \times volume^{-1}]$.

Analysis done in the pharmacokinetic analysis set (PAS). PAS consisted of all patients in FAS who had at least one blood sample providing evaluable pharmacokinetic data.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[3]	4 ^[4]	4 ^[5]	5 ^[6]
Units: hr*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	23.4 (± 13.4)	48.8 (± 26.8)	248 (± 253)	217 (± 227)
Cycle 1 Day 15	86 (± 83.7)	60.7 (± 53.2)	439 (± 687)	953 (± 1060)
Cycle 2 Day 1	58.5 (± 50.7)	48.9 (± 23.8)	550 (± 435)	328 (± 473)

Notes:

[3] - N = 4, 4, 3

[4] - N = 4, 2, 3

[5] - N = 4, 4, 3

[6] - N = 5, 4, 4

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3 ^[7]	4 ^[8]	29 ^[9]	
Units: hr*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	432 (± 260)	786 (± 702)	836 (± 770)	
Cycle 1 Day 15	2690 (± 1960)	1200 (± 960)	2890 (± 1870)	
Cycle 2 Day 1	1030 (± 551)	730 (± 815)	1050 (± 504)	

Notes:

[7] - N = 3, 4, 3

[8] - N = 4, 3, 2

[9] - N = 29, 19, 17

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Concentration after Drug Administration for BGJ398 by Treatment

End point title	Maximum Observed Concentration after Drug Administration for BGJ398 by Treatment
-----------------	--

End point description:

Pharmacokinetic parameter for BCG398.

Maximum observed concentration (C_{max}) after drug administration: $[mass \times volume^{-1}]$.

Analysis done in PAS.

End point type	Secondary
End point timeframe:	
Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1	

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[10]	4 ^[11]	6 ^[12]	5 ^[13]
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	5.75 (± 2.16)	10.5 (± 6.92)	40.1 (± 38.9)	40.6 (± 33)
Cycle 1 Day 15	13.7 (± 11.1)	9.2 (± 6.39)	77.9 (± 90)	104 (± 88.1)
Cycle 2 Day 1	12.7 (± 9.38)	9.06 (± 7.72)	43.8 (± 34.4)	37.5 (± 48.9)

Notes:

[10] - N = 4, 4, 3

[11] - N = 4, 3, 4

[12] - N = 6, 5, 4

[13] - N = 5, 5, 4

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4 ^[14]	6 ^[15]	28 ^[16]	
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	71.3 (± 45.4)	59.2 (± 50.1)	128 (± 123)	
Cycle 1 Day 15	202 (± 136)	89.4 (± 63.2)	218 (± 126)	
Cycle 2 Day 1	93.5 (± 73.1)	111 (± 86)	116 (± 69.2)	

Notes:

[14] - N = 4, 4, 4

[15] - N = 6, 4, 3

[16] - N = 28, 19, 22

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetic Parameters for BGJ398 by Treatment

End point title	Pharmacokinetic Parameters for BGJ398 by Treatment
End point description:	
Tmax=Time to reach Cmax [time].	
T1/2 = Elimination half-life associated with the terminal slope (z) of a semi logarithmic concentration-time curve [time]	
Analysis done in the PAS.	
End point type	Secondary
End point timeframe:	
Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1	

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[17]	4 ^[18]	6 ^[19]	5 ^[20]
Units: hour				
median (full range (min-max))				
Cycle 1 Day 1 (Tmax)	2.5 (2 to 3.03)	2.54 (1.92 to 4.08)	2.05 (1.93 to 3)	2.08 (2 to 3.08)
Cycle 1 Day 15 (Tmax)	2.04 (1.97 to 3)	4 (3 to 26.9)	3 (2.03 to 4.25)	3 (2 to 6)
Cycle 2 Day 1 (Tmax)	2.08 (1.93 to 3)	3.07 (2.08 to 4)	2 (2 to 2.05)	2.08 (2.08 to 4)
Cycle 1 Day 1 (T1/2)	2.51 (1.9 to 3.1)	3.08 (2.75 to 3.42)	6.77 (5.9 to 7.65)	3.22 (1.7 to 6.38)
Cycle 1 Day 15 (T1/2)	3.1 (2.76 to 6.95)	3.92 (3.92 to 3.92)	5.24 (3.38 to 11.2)	7.46 (6.4 to 33.6)
Cycle 2 Day 1 (T1/2)	2.49 (2.32 to 3.1)	3.43 (3.43 to 3.43)	6.25 (5.24 to 8.59)	4.93 (2.5 to 8.74)

Notes:

[17] - N = 4, 4, 4, 4, 3, 3

[18] - N = 4, 2, 3, 1, 4, 1

[19] - N= 6, 2, 5, 4, 4, 3

[20] - N = 5, 5, 5, 4, 4, 3

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4 ^[21]	6 ^[22]	28 ^[23]	
Units: hour				
median (full range (min-max))				
Cycle 1 Day 1 (Tmax)	2.57 (2 to 8)	2.54 (2.02 to 7.97)	2.93 (1 to 23.9)	
Cycle 1 Day 15 (Tmax)	3.07 (1 to 3.83)	3.42 (2 to 7)	2.98 (1.77 to 4.33)	
Cycle 2 Day 1 (Tmax)	2.5 (2 to 3.78)	4.08 (4 to 6)	4.02 (1.92 to 23.5)	
Cycle 1 Day 1 (T1/2)	4.69 (2.55 to 5.22)	7.95 (3.86 to 11.7)	5.39 (3 to 9.59)	
Cycle 1 Day 15 (T1/2)	20.5 (6.93 to 20.8)	6.75 (5.66 to 9.45)	12.8 (6.03 to 77.5)	
Cycle 2 Day 1 (T1/2)	6.17 (4.65 to 10)	7.73 (5.89 to 9.58)	6.64 (2.16 to 10.4)	

Notes:

[21] - N = 4, 3, 4, 3, 4, 3

[22] - N = 6, 4, 4, 3, 3, 2

[23] - N = 28, 24, 19, 17, 22, 14

Statistical analyses

No statistical analyses for this end point

Secondary: Accumulation ratio (Racc) for BGJ398 by Treatment

End point title	Accumulation ratio (Racc) for BGJ398 by Treatment
-----------------	---

End point description:

Racc = Accumulation ratio calculated as $AUC_{\tau,ss}/AUC_{\tau,dose1}$ where τ is the dosing interval where $AUC_{\tau,ss}$ is defined as the area under the concentration-time curve following multiple dosing or at steady state.

Analysis done in the PAS.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 15, Cycle 2 Day 1

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[24]	2 ^[25]	2 ^[26]	4 ^[27]
Units: accumulation ratio				
median (full range (min-max))				
Cycle 1 Day 15	3.49 (1.68 to 4.98)	2.02 (1.56 to 2.47)	4.16 (2.74 to 5.68)	5.5 (2.61 to 16.9)
Cycle 2 Day 1	2.65 (0.483 to 4.2)	1.21 (0.563 to 4.25)	1.72 (0.768 to 2.67)	1.02 (0.534 to 1.67)

Notes:

[24] - Cycle 2 Day 1 = 3

[25] - Cycle 2 Day 1 = 3

[26] - Cycle 2 Day 1 = 2

[27] - Cycle 2 Day 1 = 4

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3 ^[28]	2 ^[29]	17 ^[30]	
Units: accumulation ratio				
median (full range (min-max))				
Cycle 1 Day 15	5.26 (4.97 to 12.2)	3.18 (1.24 to 5.12)	3.79 (0.394 to 343)	
Cycle 2 Day 1	2.26 (1.77 to 4.16)	10.1 (10.1 to 10.1)	1.59 (0.744 to 34.8)	

Notes:

[28] - Cycle 2 Day 1 = 3

[29] - Cycle 2 Day 1 = 1

[30] - Cycle 2 Day 1 = 16

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration-Time Curve from Time Zero to 24 hour Post Dose for BYL719 by Treatment

End point title	Area Under the Concentration-Time Curve from Time Zero to 24 hour Post Dose for BYL719 by Treatment
-----------------	---

End point description:

Pharmacokinetic parameter for BYL719.

AUC(0-24hr) = [mass x time x volume-1].

Analysis done in the PAS.

End point type	Secondary
End point timeframe:	
Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1	

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[31]	4 ^[32]	6 ^[33]	5 ^[34]
Units: hr*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	22400 (± 1820)	31600 (± 20800)	17900 (± 6810)	18200 (± 9820)
Cycle 1 Day 15	34400 (± 10700)	16800 (± 3520)	21600 (± 7180)	19300 (± 5840)
Cycle 2 Day 1	33300 (± 10500)	30800 (± 14100)	22300 (± 16000)	23700 (± 12000)

Notes:

[31] - Cycle 1 Day 1: N=4, Cycle 1 Day 15: N=4: Cycle 2 Day 1: N=3

[32] - Cycle 1 Day 1: N=4, Cycle 1 Day 15: N=2: Cycle 2 Day 1: N=4

[33] - Cycle 1 Day 1: N=6, Cycle 1 Day 15: N=3, Cycle 2 Day 1: N=5

[34] - Cycle 1 Day 1: N=5, Cycle 1 Day 15: N=4, Cycle 2 Day 1: N=4

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4 ^[35]	3 ^[36]	26 ^[37]	
Units: hr*ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	12700 (± 7450)	19300 (± 7580)	18500 (± 7810)	
Cycle 1 Day 15	23800 (± 8320)	25200 (± 12100)	25900 (± 9800)	
Cycle 2 Day 1	25000 (± 2070)	28600 (± 8440)	25200 (± 9370)	

Notes:

[35] - Cycle 1 Day 1: N=3, Cycle 1 Day 15: N=4, Cycle 1 Day 15: N=4

[36] - Cycle 1 Day 1: N=6, Cycle 1 Day 15: N=2, Cycle 2 Day 1: N=3

[37] - Cycle 1 Day 1: N=26, Cycle 1 Day 15: N=18, Cycle 2 Day 1: N=20

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Concentration after Drug Administration for BYL719 by Treatment

End point title	Maximum Observed Concentration after Drug Administration for BYL719 by Treatment
-----------------	--

End point description:

Pharmacokinetic parameter for BYL719.

Maximum observed concentration (C_{max}) after drug administration: [mass x volume⁻¹].

Analysis done in PAS.

End point type	Secondary
End point timeframe:	
Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1	

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[38]	4 ^[39]	6 ^[40]	5 ^[41]
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	2320 (± 914)	2770 (± 1480)	2100 (± 838)	1600 (± 806)
Cycle 1 Day 15	2940 (± 1130)	1320 (± 551)	2350 (± 830)	1790 (± 686)
Cycle 2 Day 1	3600 (± 1830)	2240 (± 694)	1770 (± 898)	1730 (± 948)

Notes:

[38] - Cycle 1 Day 1: N=4

Cycle 1 Day 15: N=4

Cycle 2 Day 1: N=3

[39] - Cycle 1 Day 1: N=4

Cycle 1 Day 15: N=2

Cycle 2 Day 1: N=4

[40] - Cycle 1 Day 1: N=6

Cycle 1 Day 15: N=4

Cycle 2 Day 1: N=5

[41] - Cycle 1 Day 1: N=5

Cycle 1 Day 15: N=5

Cycle 2 Day 1: N=4

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4 ^[42]	6 ^[43]	28 ^[44]	
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	1440 (± 798)	1840 (± 1000)	1880 (± 948)	
Cycle 1 Day 15	2100 (± 533)	1490 (± 666)	2130 (± 786)	
Cycle 2 Day 1	2240 (± 614)	2340 (± 396)	2320 (± 841)	

Notes:

[42] - Cycle 1 Day 1: N=4

Cycle 1 Day 15: N=4

Cycle 2 Day 1: N=4

[43] - Cycle 1 Day 1: N=6

Cycle 1 Day 15: N=4

Cycle 2 Day 1: N=3

[44] - Cycle 1 Day 1: N=28

Cycle 1 Day 15: N=14

Cycle 2 Day 1: N=22

Statistical analyses

Secondary: Pharmacokinetic Parameters for BYL719 by Treatment

End point title	Pharmacokinetic Parameters for BYL719 by Treatment
End point description:	
Tmax=Time to reach Cmax [time].	
T1/2 = Elimination half-life associated with the terminal slope (z) of a semi logarithmic concentration-time curve [time]	
Analysis done in the PAS.	
End point type	Secondary
End point timeframe:	
Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1	

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[45]	4 ^[46]	6 ^[47]	5 ^[48]
Units: hour				
median (full range (min-max))				
Cycle 1 Day 1 (Tmax)	3.08 (1.08 to 6)	2.5 (1 to 6)	2.08 (1 to 3.47)	2 (1 to 2.08)
Cycle 1 Day 15 (Tmax)	2.5 (1.97 to 3)	3.79 (3 to 4.58)	1.08 (1 to 4.25)	4 (2 to 6)
Cycle 2 Day 1 (Tmax)	3 (1.93 to 3.33)	4.04 (2.08 to 4.13)	2 (1.08 to 6)	3.55 (2.08 to 4.15)
Cycle 1 Day 1 (T1/2)	7.73 (7.58 to 9.32)	5.72 (5.12 to 6.6)	8.76 (6.6 to 17.4)	7.46 (6.76 to 16.7)
Cycle 1 Day 15 (T1/2)	7.82 (7.35 to 14.4)	6.71 (6.71 to 6.71)	9.86 (7.88 to 17.5)	8.31 (8.21 to 10.5)
Cycle 2 Day 1 (T1/2)	8.82 (6.37 to 12.6)	7.36 (6.18 to 9.28)	7.71 (6.17 to 13.8)	8.9 (6.2 to 20.9)

Notes:

[45] - N = 4, 4, 3, 3, 4, 3

[46] - N = 4, 2, 4, 3, 1, 3

[47] - N = 6, 4, 5, 6, 3, 3

[48] - N = 5, 5, 4, 5, 3, 4

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4 ^[49]	6 ^[50]	28 ^[51]	
Units: hour				
median (full range (min-max))				
Cycle 1 Day 1 (Tmax)	1.61 (1 to 6)	2.98 (1.08 to 3.08)	2.08 (0.933 to 6.17)	
Cycle 1 Day 15 (Tmax)	3.46 (1 to 24.5)	3.87 (1.97 to 6)	3 (0.967 to 6.28)	
Cycle 2 Day 1 (Tmax)	2.38 (2 to 4)	4 (3 to 4.08)	2.99 (0.983 to 6.08)	
Cycle 1 Day 1 (T1/2)	6.38 (6.29 to 6.51)	7.05 (5.05 to 21.7)	7.45 (4.56 to 14.4)	

Cycle 1 Day 15 (T1/2)	6.96 (6.23 to 12.7)	8.42 (5.69 to 11.2)	8.24 (5.12 to 27)	
Cycle 2 Day 1 (T1/2)	5.79 (4.94 to 18.7)	7.6 (6.76 to 8.24)	6.84 (4.52 to 11.1)	

Notes:

[49] - N = 4, 4, 4, 3, 3, 4

[50] - N = 6, 4, 3, 6, 2, 3

[51] - N = 28, 19, 22, 26, 18, 18

Statistical analyses

No statistical analyses for this end point

Secondary: Accumulation ratio (Racc) for BYL719 by Treatment

End point title	Accumulation ratio (Racc) for BYL719 by Treatment
-----------------	---

End point description:

Racc = Accumulation ratio calculated as $AUC_{\tau,ss}/AUC_{\tau,dose1}$ where τ is the dosing interval where $AUC_{\tau,ss}$ is defined as the area under the concentration-time curve following multiple dosing or at steady state.

Analysis done in the PAS.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 15, Cycle 2 Day 1

End point values	BGJ398 20mg + BYL719 300mg	BGJ398 20mg + BYL719 400mg	BGJ398 40mg + BYL719 300mg	BGJ398 75mg + BYL719 300mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4 ^[52]	4 ^[53]	5 ^[54]	5 ^[55]
Units: accumulation ratio				
median (full range (min-max))				
Cycle 1 Day 15	1.66 (0.974 to 2.13)	1.27 (0.989 to 1.55)	1.5 (0.659 to 1.74)	1.38 (0.842 to 3.39)
Cycle 2 Day 1	1.41 (1.03 to 1.95)	0.865 (0.662 to 5.12)	1.25 (0.764 to 1.78)	1.38 (1.24 to 2.22)

Notes:

[52] - Cycle 1 Day 15: N= 4
Cycle 2 Day 1: N=3

[53] - Cycle 1 Day 15: N= 2
Cycle 2 Day 1: N=4

[54] - Cycle 1 Day 15: N= 3
Cycle 2 Day 1: N=5

[55] - Cycle 1 Day 15: N= 4
Cycle 2 Day 1: N=5

End point values	BGJ398 90mg + BYL719 300mg	BGJ398 100mg + BYL719 300mg	BGJ398 125mg + BYL719 300mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	3 ^[56]	3 ^[57]	20 ^[58]	
Units: accumulation ratio				
median (full range (min-max))				
Cycle 1 Day 15	2.01 (1.48 to 2.08)	0.961 (0.854 to 1.07)	1.33 (0.667 to 3.26)	

Cycle 2 Day 1	2.15 (1.32 to 4.25)	1.62 (1.23 to 2.76)	1.44 (0.752 to 2.64)	
---------------	---------------------	---------------------	----------------------	--

Notes:

[56] - Cycle 1 Day 15: N= 3

Cycle 2 Day 1: N=3

[57] - Cycle 1 Day 15: N= 2

Cycle 2 Day 1: N=3

[58] - Cycle 1 Day 15: N= 15

Cycle 2 Day 1: N=20

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.

Adverse event reporting additional description:

Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious Adverse Events field "number of deaths resulting from adverse events" all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	BGJ398 20mg@+ BYL719 300mg
-----------------------	----------------------------

Reporting group description:

BGJ398 20mg@+ BYL719 300mg

Reporting group title	BGJ398 20mg@+ BYL719 400mg
-----------------------	----------------------------

Reporting group description:

BGJ398 20mg@+ BYL719 400mg

Reporting group title	BGJ398 40mg@+ BYL719 300mg
-----------------------	----------------------------

Reporting group description:

BGJ398 40mg@+ BYL719 300mg

Reporting group title	BGJ398 75mg@+ BYL719 300mg
-----------------------	----------------------------

Reporting group description:

BGJ398 75mg@+ BYL719 300mg

Reporting group title	BGJ398 90mg@+ BYL719 300mg
-----------------------	----------------------------

Reporting group description:

BGJ398 90mg@+ BYL719 300mg

Reporting group title	BGJ398 100mg@+ BYL719 300mg
-----------------------	-----------------------------

Reporting group description:

BGJ398 100mg@+ BYL719 300mg

Reporting group title	BGJ398 125mg@+ BYL719 300mg
-----------------------	-----------------------------

Reporting group description:

BGJ398 125mg@+ BYL719 300mg

Reporting group title	All@subjects
-----------------------	--------------

Reporting group description:

All@subjects

Serious adverse events	BGJ398 20mg@+ BYL719 300mg	BGJ398 20mg@+ BYL719 400mg	BGJ398 40mg@+ BYL719 300mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	2 / 4 (50.00%)	3 / 6 (50.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
TUMOUR PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMATOMA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ILIAC VEIN OCCLUSION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			

subjects affected / exposed	2 / 4 (50.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders HYPERSENSITIVITY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders DYSпноEA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PLEURAL EFFUSION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders DISORIENTATION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Injury, poisoning and procedural complications FRACTURE			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
WOUND DECOMPOSITION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders HEADACHE			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERONEAL NERVE PALSY			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIARRHOEA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPHAGIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL HAEMORRHAGE			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
STOMATITIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
RASH MACULO-PAPULAR			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
RENAL FAILURE			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URETERIC OBSTRUCTION			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCULAR WEAKNESS			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

PAIN IN EXTREMITY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
CLOSTRIDIUM DIFFICILE COLITIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SEPTIC SHOCK			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SKIN INFECTION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
HYPERGLYCAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HYPONATRAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serious adverse events	BGJ398 75mg@+ BYL719 300mg	BGJ398 90mg@+ BYL719 300mg	BGJ398 100mg@+ BYL719 300mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 6 (66.67%)	0 / 5 (0.00%)	3 / 6 (50.00%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
TUMOUR PAIN			

subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
HAEMATOMA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
ILIAC VEIN OCCLUSION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PERIPHERAL SWELLING			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PYREXIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Immune system disorders HYPERSENSITIVITY subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Respiratory, thoracic and mediastinal disorders DYSпноEA subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
PLEURAL EFFUSION subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Psychiatric disorders DISORIENTATION subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Injury, poisoning and procedural complications FRACTURE subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 6 (16.67%) 0 / 1 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
WOUND DECOMPOSITION subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Nervous system disorders HEADACHE subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
PERONEAL NERVE PALSY			

subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
ABDOMINAL PAIN LOWER			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CONSTIPATION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DIARRHOEA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
DYSPHAGIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
NAUSEA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
RECTAL HAEMORRHAGE			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SMALL INTESTINAL OBSTRUCTION			

subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
STOMATITIS			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
RASH MACULO-PAPULAR			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
RENAL FAILURE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
URETERIC OBSTRUCTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations CLOSTRIDIUM DIFFICILE COLITIS subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
SEPTIC SHOCK subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	1 / 6 (16.67%) 0 / 1 0 / 0
SKIN INFECTION subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
Metabolism and nutrition disorders HYPERGLYCAEMIA subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0
HYPONATRAEMIA subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 6 (0.00%) 0 / 0 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0	0 / 6 (0.00%) 0 / 0 0 / 0

Serious adverse events	BGJ398 125mg@+ BYL719 300mg	All@subjects	
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 31 (35.48%)	27 / 62 (43.55%)	
number of deaths (all causes)	2	3	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) TUMOUR PAIN subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 31 (3.23%) 0 / 1 0 / 0	1 / 62 (1.61%) 0 / 1 0 / 0	
Vascular disorders DEEP VEIN THROMBOSIS			

subjects affected / exposed	0 / 31 (0.00%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATOMA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ILIAC VEIN OCCLUSION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
GENERAL PHYSICAL HEALTH DETERIORATION			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
OEDEMA PERIPHERAL			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYREXIA			
subjects affected / exposed	1 / 31 (3.23%)	4 / 62 (6.45%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
HYPERSENSITIVITY			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Respiratory, thoracic and mediastinal disorders			
DYSпноEA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLEURAL EFFUSION			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
DISORIENTATION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Injury, poisoning and procedural complications			
FRACTURE			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WOUND DECOMPOSITION			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
HEADACHE			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PERONEAL NERVE PALSY			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
ANAEMIA			

subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
ABDOMINAL PAIN LOWER			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONSTIPATION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIARRHOEA			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSPHAGIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
NAUSEA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
STOMATITIS			

subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
RASH MACULO-PAPULAR			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
RENAL FAILURE			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETERIC OBSTRUCTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
CLOSTRIDIUM DIFFICILE COLITIS			

subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEPTIC SHOCK			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN INFECTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
HYPERGLYCAEMIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPONATRAEMIA			
subjects affected / exposed	1 / 31 (3.23%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	BGJ398 20mg@+ BYL719 300mg	BGJ398 20mg@+ BYL719 400mg	BGJ398 40mg@+ BYL719 300mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	4 / 4 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
TUMOUR PAIN			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

HYPERTENSION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPOTENSION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	2
FATIGUE			
subjects affected / exposed	3 / 4 (75.00%)	3 / 4 (75.00%)	4 / 6 (66.67%)
occurrences (all)	3	3	5
CHILLS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
GAIT DISTURBANCE			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
INJECTION SITE HAEMATOMA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MASS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
LOCALISED OEDEMA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUCOSAL INFLAMMATION			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
OEDEMA PERIPHERAL			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
SUPRAPUBIC PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
HYPERSENSITIVITY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
DRY THROAT			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
COUGH			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	5
DYSPHONIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSPNOEA			
subjects affected / exposed	2 / 4 (50.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
DYSPNOEA EXERTIONAL			

subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
EPISTAXIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMOPTYSIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HICCUPS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
OROPHARYNGEAL PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PLEURAL EFFUSION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
PLEURITIC PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WHEEZING			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
PRODUCTIVE COUGH			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
DEPRESSION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
INSOMNIA			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

IRRITABILITY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
AMYLASE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
BLOOD 1,25-DIHYDROXYCHOLECALCIFEROL INCREASED			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
BLOOD 25-HYDROXYCHOLECALCIFEROL DECREASED			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	3
BLOOD CREATINE PHOSPHOKINASE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
BLOOD CREATININE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ELECTROCARDIOGRAM QT			

PROLONGED			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
LIPASE INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
LYMPHOCYTE COUNT DECREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PLATELET COUNT DECREASED			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
TRANSAMINASES INCREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
WEIGHT DECREASED			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
CONTUSION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Cardiac disorders			
TACHYCARDIA			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
AMNESIA			

subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
APHASIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BALANCE DISORDER			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSARTHRIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DIZZINESS			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
DYSGEUSIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HEADACHE			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPERAESTHESIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOAESTHESIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
LETHARGY			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
NEUROPATHY PERIPHERAL			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PERONEAL NERVE PALSY			

subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SYNCOPE			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	3
LEUKOPENIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LYMPHOPENIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
EAR DISCOMFORT			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VERTIGO			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
CHORIORETINOPATHY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DIPLOPIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DRY EYE			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
KERATITIS			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OCULAR HYPERAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PERIORBITAL OEDEMA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RETINAL DETACHMENT			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VISION BLURRED			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
ABDOMINAL PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ANAL FISSURE			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ASCITES			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHEILITIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

CONSTIPATION			
subjects affected / exposed	1 / 4 (25.00%)	2 / 4 (50.00%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
DIARRHOEA			
subjects affected / exposed	3 / 4 (75.00%)	2 / 4 (50.00%)	5 / 6 (83.33%)
occurrences (all)	4	4	7
DRY MOUTH			
subjects affected / exposed	1 / 4 (25.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	1	2	1
DYSPEPSIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
DYSPHAGIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTRITIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GINGIVAL PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MELAENA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NAUSEA			
subjects affected / exposed	3 / 4 (75.00%)	1 / 4 (25.00%)	4 / 6 (66.67%)
occurrences (all)	4	2	4
PROCTALGIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
STOMATITIS			

subjects affected / exposed	1 / 4 (25.00%)	2 / 4 (50.00%)	2 / 6 (33.33%)
occurrences (all)	1	3	2
VOMITING			
subjects affected / exposed	1 / 4 (25.00%)	1 / 4 (25.00%)	2 / 6 (33.33%)
occurrences (all)	1	4	2
Skin and subcutaneous tissue disorders			
ALOPECIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
BLISTER			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DRY SKIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ERYTHEMA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NAIL BED INFLAMMATION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NAIL DISORDER			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRURITUS			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
RASH			
subjects affected / exposed	0 / 4 (0.00%)	2 / 4 (50.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
RASH ERYTHEMATOUS			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
RASH MACULO-PAPULAR			
subjects affected / exposed	1 / 4 (25.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	1	1	2
RASH PRURITIC			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
SKIN FISSURES			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
SKIN LESION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN NECROSIS			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
XERODERMA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
DYSURIA			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
ACUTE KIDNEY INJURY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
MICTURITION DISORDER			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MICTURITION URGENCY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
POLLAKIURIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

URINARY RETENTION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT OBSTRUCTION			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
URINARY TRACT PAIN			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BACK PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
FLANK PAIN			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUSCLE SPASMS			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
MYALGIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PAIN IN EXTREMITY			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Infections and infestations			
ANAL INFECTION			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
CELLULITIS			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
CONJUNCTIVITIS			

subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CYSTITIS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INFECTION			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
INFLUENZA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
MUCOSAL INFECTION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RASH PUSTULAR			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN INFECTION			
subjects affected / exposed	2 / 4 (50.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
URINARY TRACT INFECTION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
VAGINAL INFECTION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
VULVOVAGINAL MYCOTIC INFECTION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			

DECREASED APPETITE			
subjects affected / exposed	2 / 4 (50.00%)	1 / 4 (25.00%)	2 / 6 (33.33%)
occurrences (all)	2	1	2
DEHYDRATION			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPERCALCAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPERKALAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPERGLYCAEMIA			
subjects affected / exposed	1 / 4 (25.00%)	2 / 4 (50.00%)	4 / 6 (66.67%)
occurrences (all)	1	4	4
HYPERPHOSPHATAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOALBUMINAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOCALCAEMIA			
subjects affected / exposed	1 / 4 (25.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPOCHLORAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
HYPOKALAEMIA			
subjects affected / exposed	2 / 4 (50.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
HYPOMAGNESAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPONATRAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	1 / 4 (25.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0

HYPOPHOSPHATAEMIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
POLYDIPSIA			
subjects affected / exposed	0 / 4 (0.00%)	0 / 4 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Non-serious adverse events	BGJ398 75mg@+ BYL719 300mg	BGJ398 90mg@+ BYL719 300mg	BGJ398 100mg@+ BYL719 300mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)	5 / 5 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
TUMOUR PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPERTENSION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPOTENSION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
FATIGUE			
subjects affected / exposed	3 / 6 (50.00%)	4 / 5 (80.00%)	3 / 6 (50.00%)
occurrences (all)	4	5	3
CHILLS			

subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
GAIT DISTURBANCE			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INJECTION SITE HAEMATOMA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
MASS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LOCALISED OEDEMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUCOSAL INFLAMMATION			
subjects affected / exposed	0 / 6 (0.00%)	3 / 5 (60.00%)	1 / 6 (16.67%)
occurrences (all)	0	4	2
NON-CARDIAC CHEST PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OEDEMA PERIPHERAL			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	2 / 6 (33.33%)
occurrences (all)	2	0	3
PERIPHERAL SWELLING			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PYREXIA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
SUPRAPUBIC PAIN			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Immune system disorders			

HYPERSENSITIVITY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
DRY THROAT			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
COUGH			
subjects affected / exposed	1 / 6 (16.67%)	1 / 5 (20.00%)	2 / 6 (33.33%)
occurrences (all)	1	1	2
DYSPHONIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
DYSPNOEA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
DYSPNOEA EXERTIONAL			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
EPISTAXIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HAEMOPTYSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HICCUPS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
OROPHARYNGEAL PAIN			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
PLEURAL EFFUSION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PLEURITIC PAIN			

subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
WHEEZING			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PRODUCTIVE COUGH			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
DEPRESSION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	1	0	1
INSOMNIA			
subjects affected / exposed	1 / 6 (16.67%)	2 / 5 (40.00%)	1 / 6 (16.67%)
occurrences (all)	1	2	1
IRRITABILITY			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
AMYLASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	0	2	1
BLOOD 1,25-DIHYDROXYCHOLECALCIFEROL INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

BLOOD 25-HYDROXYCHOLECALCIFEROL DECREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	0	2	1
BLOOD CREATINE PHOSPHOKINASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
BLOOD CREATININE INCREASED			
subjects affected / exposed	1 / 6 (16.67%)	2 / 5 (40.00%)	4 / 6 (66.67%)
occurrences (all)	1	3	4
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
GAMMA-GLUTAMYLTRANSFERASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
LIPASE INCREASED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
LYMPHOCYTE COUNT DECREASED			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
PLATELET COUNT DECREASED			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
TRANSAMINASES INCREASED			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0	0 / 6 (0.00%) 0
WEIGHT DECREASED subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	2 / 5 (40.00%) 2	2 / 6 (33.33%) 2
WHITE BLOOD CELL COUNT DECREASED subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0	0 / 6 (0.00%) 0
Injury, poisoning and procedural complications CONTUSION subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders TACHYCARDIA subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0	0 / 6 (0.00%) 0
Nervous system disorders AMNESIA subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0	0 / 6 (0.00%) 0
APHASIA subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 5 (0.00%) 0	0 / 6 (0.00%) 0
BALANCE DISORDER subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 5 (0.00%) 0	1 / 6 (16.67%) 1
DYSARTHRIA subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	1 / 5 (20.00%) 1	0 / 6 (0.00%) 0
DIZZINESS subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 5 (20.00%) 2	0 / 6 (0.00%) 0
DYSGEUSIA subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 5 (40.00%) 2	2 / 6 (33.33%) 2
HEADACHE			

subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPERAESTHESIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPOAESTHESIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LETHARGY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NEUROPATHY PERIPHERAL			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
PERONEAL NERVE PALSY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SYNCOPE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	1 / 6 (16.67%)	1 / 5 (20.00%)	2 / 6 (33.33%)
occurrences (all)	1	1	2
LEUKOPENIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
LYMPHOPENIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
THROMBOCYTOPENIA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

Ear and labyrinth disorders EAR DISCOMFORT subjects affected / exposed occurrences (all) VERTIGO subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0 0 / 6 (0.00%) 0	0 / 5 (0.00%) 0 1 / 5 (20.00%) 1	1 / 6 (16.67%) 1 0 / 6 (0.00%) 0
Eye disorders CHORIORETINOPATHY subjects affected / exposed occurrences (all) DIPLOPIA subjects affected / exposed occurrences (all) DRY EYE subjects affected / exposed occurrences (all) KERATITIS subjects affected / exposed occurrences (all) OCULAR HYPERAEMIA subjects affected / exposed occurrences (all) PERIORBITAL OEDEMA subjects affected / exposed occurrences (all) RETINAL DETACHMENT subjects affected / exposed occurrences (all) VISION BLURRED subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 1 / 6 (16.67%) 2 0 / 6 (0.00%) 0 1 / 6 (16.67%) 1 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0	1 / 5 (20.00%) 2 1 / 5 (20.00%) 1 1 / 5 (20.00%) 1 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0 0 / 5 (0.00%) 0	0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 1 / 6 (16.67%) 1 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 1 / 6 (16.67%) 1
Gastrointestinal disorders ABDOMINAL DISCOMFORT subjects affected / exposed occurrences (all) ABDOMINAL DISTENSION	1 / 6 (16.67%) 2	0 / 5 (0.00%) 0	0 / 6 (0.00%) 0

subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
ABDOMINAL PAIN			
subjects affected / exposed	1 / 6 (16.67%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
ABDOMINAL PAIN UPPER			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ANAL FISSURE			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ASCITES			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CHEILITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
CONSTIPATION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	3 / 6 (50.00%)
occurrences (all)	0	1	3
DIARRHOEA			
subjects affected / exposed	4 / 6 (66.67%)	2 / 5 (40.00%)	3 / 6 (50.00%)
occurrences (all)	5	5	3
DRY MOUTH			
subjects affected / exposed	3 / 6 (50.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	3	0	1
DYSPEPSIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
DYSPHAGIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
GASTRITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
GASTROOESOPHAGEAL REFLUX			

DISEASE			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
GINGIVAL PAIN			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
MELAENA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
NAUSEA			
subjects affected / exposed	4 / 6 (66.67%)	1 / 5 (20.00%)	3 / 6 (50.00%)
occurrences (all)	4	1	3
PROCTALGIA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
STOMATITIS			
subjects affected / exposed	3 / 6 (50.00%)	3 / 5 (60.00%)	2 / 6 (33.33%)
occurrences (all)	4	3	2
VOMITING			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	3 / 6 (50.00%)
occurrences (all)	1	0	3
Skin and subcutaneous tissue disorders			
ALOPECIA			
subjects affected / exposed	1 / 6 (16.67%)	2 / 5 (40.00%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
BLISTER			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
DRY SKIN			
subjects affected / exposed	1 / 6 (16.67%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
ERYTHEMA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
NAIL BED INFLAMMATION			

subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
NAIL DISORDER			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
PRURITUS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RASH			
subjects affected / exposed	0 / 6 (0.00%)	2 / 5 (40.00%)	1 / 6 (16.67%)
occurrences (all)	0	2	1
RASH ERYTHEMATOUS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
RASH MACULO-PAPULAR			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
RASH PRURITIC			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN FISSURES			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
SKIN LESION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SKIN NECROSIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
XERODERMA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0

Renal and urinary disorders			
DYSURIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
ACUTE KIDNEY INJURY			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
MICTURITION DISORDER			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MICTURITION URGENCY			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
POLLAKIURIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY RETENTION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
URINARY TRACT OBSTRUCTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
ARTHRALGIA			
subjects affected / exposed	2 / 6 (33.33%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	2	1	1
BACK PAIN			
subjects affected / exposed	1 / 6 (16.67%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
FLANK PAIN			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
MUSCLE SPASMS			

subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
MYALGIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Infections and infestations			
ANAL INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CELLULITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CONJUNCTIVITIS			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
CYSTITIS			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
INFLUENZA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
MUCOSAL INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
RASH PUSTULAR			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
SKIN INFECTION			
subjects affected / exposed	2 / 6 (33.33%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0

UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
URINARY TRACT INFECTION			
subjects affected / exposed	2 / 6 (33.33%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	2	1	1
VAGINAL INFECTION			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
VULVOVAGINAL MYCOTIC INFECTION			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	1 / 6 (16.67%)	3 / 5 (60.00%)	3 / 6 (50.00%)
occurrences (all)	1	3	3
DEHYDRATION			
subjects affected / exposed	1 / 6 (16.67%)	1 / 5 (20.00%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
HYPERCALCAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPERKALAEMIA			
subjects affected / exposed	1 / 6 (16.67%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
HYPERGLYCAEMIA			
subjects affected / exposed	4 / 6 (66.67%)	2 / 5 (40.00%)	2 / 6 (33.33%)
occurrences (all)	6	9	5
HYPERPHOSPHATAEMIA			
subjects affected / exposed	2 / 6 (33.33%)	2 / 5 (40.00%)	3 / 6 (50.00%)
occurrences (all)	3	3	4
HYPOALBUMINAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
HYPOCALCAEMIA			

subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOCHLORAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
HYPOKALAEMIA			
subjects affected / exposed	1 / 6 (16.67%)	2 / 5 (40.00%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
HYPOMAGNESAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	2 / 6 (33.33%)
occurrences (all)	0	1	2
HYPONATRAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	1 / 5 (20.00%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
HYPOPHOSPHATAEMIA			
subjects affected / exposed	0 / 6 (0.00%)	2 / 5 (40.00%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
POLYDIPSIA			
subjects affected / exposed	0 / 6 (0.00%)	0 / 5 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	BGJ398 125mg@+ BYL719 300mg	All@subjects	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	31 / 31 (100.00%)	62 / 62 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) TUMOUR PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
HYPERTENSION			
subjects affected / exposed	0 / 31 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
HYPOTENSION			

subjects affected / exposed	2 / 31 (6.45%)	3 / 62 (4.84%)	
occurrences (all)	2	3	
ORTHOSTATIC HYPOTENSION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	7 / 31 (22.58%)	11 / 62 (17.74%)	
occurrences (all)	10	15	
FATIGUE			
subjects affected / exposed	14 / 31 (45.16%)	34 / 62 (54.84%)	
occurrences (all)	17	40	
CHILLS			
subjects affected / exposed	3 / 31 (9.68%)	5 / 62 (8.06%)	
occurrences (all)	3	5	
GAIT DISTURBANCE			
subjects affected / exposed	0 / 31 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
INJECTION SITE HAEMATOMA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
MASS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
LOCALISED OEDEMA			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
MUCOSAL INFLAMMATION			
subjects affected / exposed	10 / 31 (32.26%)	15 / 62 (24.19%)	
occurrences (all)	16	23	
NON-CARDIAC CHEST PAIN			

subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
OEDEMA PERIPHERAL			
subjects affected / exposed	3 / 31 (9.68%)	7 / 62 (11.29%)	
occurrences (all)	3	9	
PERIPHERAL SWELLING			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
PYREXIA			
subjects affected / exposed	4 / 31 (12.90%)	6 / 62 (9.68%)	
occurrences (all)	6	9	
SUPRAPUBIC PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Immune system disorders			
HYPERSENSITIVITY			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	3	3	
Respiratory, thoracic and mediastinal disorders			
DRY THROAT			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
COUGH			
subjects affected / exposed	3 / 31 (9.68%)	10 / 62 (16.13%)	
occurrences (all)	3	12	
DYSPHONIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
DYSPNOEA			
subjects affected / exposed	5 / 31 (16.13%)	9 / 62 (14.52%)	
occurrences (all)	5	9	
DYSPNOEA EXERTIONAL			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
EPISTAXIS			

subjects affected / exposed	4 / 31 (12.90%)	4 / 62 (6.45%)	
occurrences (all)	5	5	
HAEMOPTYSIS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
HICCUPS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
OROPHARYNGEAL PAIN			
subjects affected / exposed	2 / 31 (6.45%)	4 / 62 (6.45%)	
occurrences (all)	3	5	
PLEURAL EFFUSION			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences (all)	1	3	
PLEURITIC PAIN			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
WHEEZING			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
PRODUCTIVE COUGH			
subjects affected / exposed	1 / 31 (3.23%)	3 / 62 (4.84%)	
occurrences (all)	1	3	
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	1 / 31 (3.23%)	3 / 62 (4.84%)	
occurrences (all)	1	3	
DEPRESSION			
subjects affected / exposed	2 / 31 (6.45%)	5 / 62 (8.06%)	
occurrences (all)	2	5	
INSOMNIA			
subjects affected / exposed	3 / 31 (9.68%)	8 / 62 (12.90%)	
occurrences (all)	3	8	
IRRITABILITY			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	

Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	10 / 31 (32.26%)	12 / 62 (19.35%)	
occurrences (all)	11	13	
AMYLASE INCREASED			
subjects affected / exposed	2 / 31 (6.45%)	4 / 62 (6.45%)	
occurrences (all)	2	4	
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	8 / 31 (25.81%)	11 / 62 (17.74%)	
occurrences (all)	11	15	
BLOOD 1,25-DIHYDROXYCHOLECALCIFEROL INCREASED			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	2	
BLOOD 25-HYDROXYCHOLECALCIFEROL DECREASED			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	3 / 31 (9.68%)	6 / 62 (9.68%)	
occurrences (all)	3	9	
BLOOD CREATINE PHOSPHOKINASE INCREASED			
subjects affected / exposed	1 / 31 (3.23%)	3 / 62 (4.84%)	
occurrences (all)	1	3	
BLOOD CREATININE INCREASED			
subjects affected / exposed	10 / 31 (32.26%)	18 / 62 (29.03%)	
occurrences (all)	24	33	
BLOOD LACTATE DEHYDROGENASE INCREASED			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
ELECTROCARDIOGRAM QT PROLONGED			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
GAMMA-GLUTAMYLTRANSFERASE			

INCREASED			
subjects affected / exposed	6 / 31 (19.35%)	8 / 62 (12.90%)	
occurrences (all)	8	10	
LIPASE INCREASED			
subjects affected / exposed	4 / 31 (12.90%)	7 / 62 (11.29%)	
occurrences (all)	7	11	
LYMPHOCYTE COUNT DECREASED			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences (all)	1	3	
PLATELET COUNT DECREASED			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences (all)	2	3	
TRANSAMINASES INCREASED			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
WEIGHT DECREASED			
subjects affected / exposed	5 / 31 (16.13%)	12 / 62 (19.35%)	
occurrences (all)	5	12	
WHITE BLOOD CELL COUNT DECREASED			
subjects affected / exposed	3 / 31 (9.68%)	3 / 62 (4.84%)	
occurrences (all)	4	4	
Injury, poisoning and procedural complications			
CONTUSION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Cardiac disorders			
TACHYCARDIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Nervous system disorders			
AMNESIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
APHASIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	

BALANCE DISORDER		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
DYSARTHRIA		
subjects affected / exposed	0 / 31 (0.00%)	2 / 62 (3.23%)
occurrences (all)	0	2
DIZZINESS		
subjects affected / exposed	2 / 31 (6.45%)	4 / 62 (6.45%)
occurrences (all)	3	6
DYSGEUSIA		
subjects affected / exposed	11 / 31 (35.48%)	17 / 62 (27.42%)
occurrences (all)	12	18
HEADACHE		
subjects affected / exposed	5 / 31 (16.13%)	6 / 62 (9.68%)
occurrences (all)	6	7
HYPERAESTHESIA		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
HYPOAESTHESIA		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
LETHARGY		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
NEUROPATHY PERIPHERAL		
subjects affected / exposed	3 / 31 (9.68%)	4 / 62 (6.45%)
occurrences (all)	3	4
PERIPHERAL SENSORY NEUROPATHY		
subjects affected / exposed	2 / 31 (6.45%)	3 / 62 (4.84%)
occurrences (all)	2	3
PERONEAL NERVE PALSY		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
SYNCOPE		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1

Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	5 / 31 (16.13%)	11 / 62 (17.74%)	
occurrences (all)	13	21	
LEUKOPENIA			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
LYMPHOPENIA			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	3	3	
THROMBOCYTOPENIA			
subjects affected / exposed	4 / 31 (12.90%)	5 / 62 (8.06%)	
occurrences (all)	6	7	
Ear and labyrinth disorders			
EAR DISCOMFORT			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
VERTIGO			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Eye disorders			
CHORIORETINOPATHY			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	2	
DIPLOPIA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
DRY EYE			
subjects affected / exposed	7 / 31 (22.58%)	8 / 62 (12.90%)	
occurrences (all)	7	8	
KERATITIS			
subjects affected / exposed	2 / 31 (6.45%)	4 / 62 (6.45%)	
occurrences (all)	4	7	
OCULAR HYPERAEMIA			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
PERIORBITAL OEDEMA			

subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
RETINAL DETACHMENT			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
VISION BLURRED			
subjects affected / exposed	4 / 31 (12.90%)	5 / 62 (8.06%)	
occurrences (all)	5	6	
Gastrointestinal disorders			
ABDOMINAL DISCOMFORT			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	2	
ABDOMINAL DISTENSION			
subjects affected / exposed	0 / 31 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	3	
ABDOMINAL PAIN			
subjects affected / exposed	5 / 31 (16.13%)	8 / 62 (12.90%)	
occurrences (all)	5	8	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	3 / 31 (9.68%)	4 / 62 (6.45%)	
occurrences (all)	4	5	
ANAL FISSURE			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
ASCITES			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
CHEILITIS			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
CONSTIPATION			
subjects affected / exposed	8 / 31 (25.81%)	15 / 62 (24.19%)	
occurrences (all)	11	18	
DIARRHOEA			
subjects affected / exposed	19 / 31 (61.29%)	38 / 62 (61.29%)	
occurrences (all)	35	63	

DRY MOUTH		
subjects affected / exposed	11 / 31 (35.48%)	18 / 62 (29.03%)
occurrences (all)	12	20
DYSPEPSIA		
subjects affected / exposed	4 / 31 (12.90%)	5 / 62 (8.06%)
occurrences (all)	7	9
DYSPHAGIA		
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)
occurrences (all)	1	2
GASTRITIS		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
GASTROOESOPHAGEAL REFLUX DISEASE		
subjects affected / exposed	0 / 31 (0.00%)	3 / 62 (4.84%)
occurrences (all)	0	3
GINGIVAL PAIN		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
MELAENA		
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)
occurrences (all)	1	2
NAUSEA		
subjects affected / exposed	15 / 31 (48.39%)	31 / 62 (50.00%)
occurrences (all)	22	40
PROCTALGIA		
subjects affected / exposed	1 / 31 (3.23%)	4 / 62 (6.45%)
occurrences (all)	1	4
STOMATITIS		
subjects affected / exposed	15 / 31 (48.39%)	28 / 62 (45.16%)
occurrences (all)	31	46
VOMITING		
subjects affected / exposed	13 / 31 (41.94%)	21 / 62 (33.87%)
occurrences (all)	17	28
Skin and subcutaneous tissue disorders		

ALOPECIA		
subjects affected / exposed	8 / 31 (25.81%)	12 / 62 (19.35%)
occurrences (all)	8	12
BLISTER		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
DRY SKIN		
subjects affected / exposed	6 / 31 (19.35%)	10 / 62 (16.13%)
occurrences (all)	7	11
ERYTHEMA		
subjects affected / exposed	4 / 31 (12.90%)	4 / 62 (6.45%)
occurrences (all)	5	5
NAIL BED INFLAMMATION		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
NAIL DISORDER		
subjects affected / exposed	3 / 31 (9.68%)	3 / 62 (4.84%)
occurrences (all)	4	4
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME		
subjects affected / exposed	6 / 31 (19.35%)	7 / 62 (11.29%)
occurrences (all)	9	10
PRURITUS		
subjects affected / exposed	2 / 31 (6.45%)	3 / 62 (4.84%)
occurrences (all)	2	3
RASH		
subjects affected / exposed	5 / 31 (16.13%)	10 / 62 (16.13%)
occurrences (all)	5	10
RASH ERYTHEMATOUS		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	2
RASH MACULO-PAPULAR		
subjects affected / exposed	4 / 31 (12.90%)	8 / 62 (12.90%)
occurrences (all)	4	9
RASH PRURITIC		

subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
SKIN FISSURES			
subjects affected / exposed	2 / 31 (6.45%)	4 / 62 (6.45%)	
occurrences (all)	2	4	
SKIN LESION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
SKIN NECROSIS			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
XERODERMA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Renal and urinary disorders			
DYSURIA			
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)	
occurrences (all)	2	3	
ACUTE KIDNEY INJURY			
subjects affected / exposed	0 / 31 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
MICTURITION DISORDER			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	4	4	
MICTURITION URGENCY			
subjects affected / exposed	2 / 31 (6.45%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
POLLAKIURIA			
subjects affected / exposed	2 / 31 (6.45%)	3 / 62 (4.84%)	
occurrences (all)	4	5	
URINARY RETENTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
URINARY TRACT OBSTRUCTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	

URINARY TRACT PAIN subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	2 / 62 (3.23%) 2	
Musculoskeletal and connective tissue disorders			
ARTHRALGIA subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	6 / 62 (9.68%) 6	
BACK PAIN subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	4 / 62 (6.45%) 4	
FLANK PAIN subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	2 / 62 (3.23%) 2	
MUSCLE SPASMS subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	5 / 62 (8.06%) 5	
MYALGIA subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	3 / 62 (4.84%) 3	
PAIN IN EXTREMITY subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 3	4 / 62 (6.45%) 6	
Infections and infestations			
ANAL INFECTION subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 62 (1.61%) 1	
CELLULITIS subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 62 (1.61%) 1	
CONJUNCTIVITIS subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 4	4 / 62 (6.45%) 5	
CYSTITIS subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	2 / 62 (3.23%) 2	
INFECTION			

subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
INFLUENZA			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
MUCOSAL INFECTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
RASH PUSTULAR			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
SKIN INFECTION			
subjects affected / exposed	1 / 31 (3.23%)	5 / 62 (8.06%)	
occurrences (all)	1	5	
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
URINARY TRACT INFECTION			
subjects affected / exposed	2 / 31 (6.45%)	7 / 62 (11.29%)	
occurrences (all)	2	7	
VAGINAL INFECTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
VULVOVAGINAL MYCOTIC INFECTION			
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	16 / 31 (51.61%)	28 / 62 (45.16%)	
occurrences (all)	21	33	
DEHYDRATION			
subjects affected / exposed	2 / 31 (6.45%)	5 / 62 (8.06%)	
occurrences (all)	2	5	
HYPERCALCAEMIA			

subjects affected / exposed	3 / 31 (9.68%)	3 / 62 (4.84%)
occurrences (all)	4	4
HYPERKALAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)
occurrences (all)	1	2
HYPERGLYCAEMIA		
subjects affected / exposed	9 / 31 (29.03%)	24 / 62 (38.71%)
occurrences (all)	12	41
HYPERPHOSPHATAEMIA		
subjects affected / exposed	17 / 31 (54.84%)	24 / 62 (38.71%)
occurrences (all)	35	45
HYPOALBUMINAEMIA		
subjects affected / exposed	2 / 31 (6.45%)	3 / 62 (4.84%)
occurrences (all)	2	3
HYPOCALCAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	2 / 62 (3.23%)
occurrences (all)	1	2
HYPOCHLORAEMIA		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
HYPOKALAEMIA		
subjects affected / exposed	3 / 31 (9.68%)	8 / 62 (12.90%)
occurrences (all)	5	10
HYPOMAGNESAEMIA		
subjects affected / exposed	2 / 31 (6.45%)	5 / 62 (8.06%)
occurrences (all)	2	5
HYPONATRAEMIA		
subjects affected / exposed	1 / 31 (3.23%)	4 / 62 (6.45%)
occurrences (all)	2	6
HYPOPHOSPHATAEMIA		
subjects affected / exposed	4 / 31 (12.90%)	7 / 62 (11.29%)
occurrences (all)	12	15
POLYDIPSIA		
subjects affected / exposed	0 / 31 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
27 January 2015	Guidelines for the management of pneumonitis were added as a result of implementation of an Urgent Safety Measure for BYL719. In addition, a letter was sent to all sites and Investigators participating in BYL719 studies on 19-Dec-2014 to implement Urgent Safety Measures immediately to adequately protect patients.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported